Actively Recruiting
Infusion Set Replacement Intervals for Critically Ill Patients
Led by Zhongnan Hospital · Updated on 2023-12-29
1240
Participants Needed
1
Research Sites
215 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aimed to evaluate the efficacy of 24-hour versus 96-hour infusion set replacement to prevent central line-associated bloodstream infection (CLABSI) in critically ill adults with central venous access devices.
CONDITIONS
Official Title
Infusion Set Replacement Intervals for Critically Ill Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Able to provide informed consent
- Expected length of stay in intensive care unit longer than 96 hours
- Need for treatment with a central venous access device
- Central venous access device expected to remain in place for at least 96 hours with infusion set attached
You will not qualify if you...
- Bloodstream infection within 48 hours after ICU admission
- Vascular access device removed within 96 hours after ICU admission
- Participation in other clinical studies within the past 2 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430070
Actively Recruiting
Research Team
B
Bo Hu, MD
CONTACT
F
Fen Hu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here